The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses

Biomarker Research

Correspondence

Hao Sun¹  Xinggui Chen²  Chaoyong Liang³  Yungchang Chen⁴  Tongyu Lin⁵  He Huang⁶  Huawei Weng⁶  Hongqiang Guo⁷  Hongyu Zhang⁸  Sheng Ye⁹  Yanhong Deng^1,10  Yang Liu^1,11  Anxin Gu^1,12  Mingyan E^1,12  Xingxiang Pu^1,13  Yaru Zhang^1,14  Mengmeng Wu^1,14  Yutong Ma^1,14  Xue Wu^1,14  Qiuxiang Ou^1,14  Chunman Wu^1,14  Yang Shao^1,15 

[1] Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, 400030, Chongqing, China;Department of Medical Oncology, Cancer Center, Affiliated Hospital of Guangdong Medical University, 524023, Zhanjiang, China;Department of Medical Oncology, Guangxi Medical University Cancer Hospital, 530021, Nanning, China;Department of Medical Oncology, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, 610041, Chengdu, Sichuan, China;Department of Medical Oncology, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, 610041, Chengdu, Sichuan, China;Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, China;Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, China;Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, China;Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, China;Department of Medical Oncology, The First Affiliated Hospital of Sun Yat-sen University, 510080, Guangzhou, China;Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, 510655, Guangzhou, China;Department of Pathology, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, 610041, Chengdu, China;Department of Radiation Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Nangang District, 150040, Harbin, Heilongjiang, China;Department of Thoracic Medical Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 283 Tongzipo Road, Yuelu District, 410013, Changsha, China;Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, 210000, Nanjing, China;Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, 210000, Nanjing, China;School of Public Health, Nanjing Medical University, 211166, Nanjing, China;

关键词: BRAF;    Colorectal cancer;    Next-generation sequencing;    Prognosis;   

DOI  :  10.1186/s40364-022-00443-8

 received in 2022-08-10, accepted in 2022-12-15,  发布年份 2022

来源: Springer

【 摘 要 】

BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups. 

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 2

Fig. 5